An aerosol suspension formulation (I) comprises 1,1,1,2,3,3,3-heptafluoropropane (HFC-227), 1-10% ethanol, micronised mometasone furoate (II) at a concentration of at least 1% of the ethanol concentration and optionally a surfactant. Also claimed are: a method for treating allergic reactions in the respiratory tract by inhalation of (I); and a metered dose inhaler containing (I).
展开▼